Review reveals treatment strategies using engineered probiotics and synthetic biology for diabetic retinopathy management, suggesting personalized therapies.
Diabetic retinopathy (DR), a complex condition driven by inflammation, oxidative stress, and metabolic imbalances, calls for innovative treatment strategies. Engineered probiotics delivering angiotensin-converting enzyme 2 (ACE2) offer a promising strategy by leveraging gut microbiome-retina association. Advances in synthetic biology and computational techniques enable personalized, data-driven therapies. This review discusses computational approaches at multiple scales and presents an integrated framework for promoting personalized, systems-level DR management.
No takes yet. Share an insight, caveat, or question.
Dehkordi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: